|Home | About | Journals | Submit | Contact Us | Français|
Dihydrolipoamide dehydrogenase (DLDH) is a multifunctional oxidoreductase and is well known as an essential component of four mammalian mitochondrial multienzyme complexes: pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, branched chain α-keto acid dehydrogenase, and the glycine cleavage system. However, existence of extracellular DLDH in mammals, if any, has not been clearly defined. The present article reports identification and biochemical characterization of serum DLDH. Proteomic analysis of rat serum using blue native polyacrylamide gel electrophoresis (BN-PAGE) and mass spectrometry peptide sequencing led to generation of 6 tryptic peptides in one band that matched to mitochondrial DLDH, indicating the existence of DLDH in rat serum. Measurement of enzymatic activity also indicated the existence of DLDH in human and mouse serum. Further biochemical analysis of rat serum DLDH revealed that this enzyme lacked diaphorase activity and could not be detected on Western blots probed with antibodies that recognized mitochondrial DLDH. Moreover, both ammonium sulfate fractioning and gel filtration of serum samples rendered a great loss in DLDH activity, indicating that the enzyme activity of this serum protein, unlike that of mitochondrial DLDH, is very labile. When DTT was supplemented in the buffer used for gel filtration, DLDH activity was found to be largely preserved; indicating that serum DLDH is susceptible to air-implicated inactivation. Results of the present study indicate that serum DLDH differs from mitochondrial DLDH in that it is a very labile enzyme.
Dihydrolipoamide dehydrogenase (DLDH) is a multifunctional, flavin-dependent, pyridine nucleotide disulfide oxidoreductase . It is an integral component of five multi-enzyme protein complexes, including pyruvate dehydrogenase complex, α-ketoglutarate dehydrogenase complex, branched chain amino acid dehydrogenase complex, glycine cleavage system, and acetoin dehydrogenase complex . Among these complexes, the first three are often collectively called 2-oxo-acid or α-keto acid dehydrogenase complexes . With the exception of the acetoin dehydrogenase complex that exists only in certain bacteria such as Klebsiella pneumonia , all the other complexes are present in mitochondria, wherein DLDH is an extremely stable homodimer [5, 6] that catalyzes the reoxidation of acyltransferase (E2)-linked dihydrolipoamide to lipoamide using NAD+ as the electron acceptor via a disulfide relay mechanism [7, 8]. In vitro, DLDH can also catalyze NADH-dependent reduction of free lipoamide, a reaction that is usually termed the reverse reaction . Moreover, DLDH has diaphorase activity that catalyzes NADH-dependent reduction of a variety of electron acceptors such as 2,6-dichlorophenolindophenol (DCPIP), nitro blue tetrazolium (NBT) [9, 10], ubiquinone [11, 12], and nitric oxide (NO) . Most importantly, when dysfunctional, DLDH stimulates overproduction of reactive oxygen species and thereby causes oxidative stress [14–16]. On the other hand, a functional DLDH can serve as a protective enzyme under oxidative stress conditions [17, 18]. Additionally, DLDH also possesses metal-binding properties in certain bacteria and plants [19, 20] and has DNA binding properties that can regulate protein synthesis [21–23]. More recently, it has been reported that DLDH inhibition via RNA interference can modulate the life span of C. elegans  and that DLDH in this organism is also involved in mediating cellular resistance to phosphine toxicity . These findings demonstrate that DLDH is truly a multifunctional oxidoreductase.
Most organisms contain only one form of DLDH. Exceptions, however, do exist. For example, there are two forms of DLDH in E. coli [26, 27]. One form plays the classical role in the aforementioned enzyme complexes , while the other is involved in transportation of carbohydrates . The two forms of DLDH mainly differ in their molecular weight. Pseudomonas putida is the only organism that contains three forms of DLDH [28–30]. Additionally, arabidopsis mitochondria contain two forms of DLDH that are interchangeable among the different enzyme complexes  and the human malaria parasite Plasmodium falciparum own two distinct DLDHs . In contrast, in mammals all the DLDH contained in the above mentioned mitochondrial protein complexes are reportedly encoded by a same single gene and no additional forms of this protein have been definitively identified . Although several reports have described the observations of DLDH isoforms in eukaryotes, the findings are most likely due to a conformational isomerism [34, 35] or an immunological isomerism .
Interestingly, it was reported in 1970’s and 1980’s that DLDH existed in human serum [37–39] wherein no 2-oxo-acid dehydrogenase complexes are present. Nonetheless, whether the biochemical property of serum DLDH is identical to that of mitochondrial DLDH is unknown. Moreover, in those earlier studies, enzyme activity was the only proof that DLDH exists in serum and no other biochemical characterization of this serum protein has been reported. In our proteomic studies of rat serum proteins using blue native gel electrophoresis and mass spectrometry peptide sequencing, we found that DLDH also exists in rat serum . We now report herein our further characterization of this serum enzyme. Results of the present studies indicate that serum DLDH is a labile enzyme.
Ammonium sulfate [(NH4)2SO4] and dithiothreitol (DTT) were purchased from Sigma. Ammonium persulfate, bis-acrylamide, acrylamide and Coomassie brilliant blue (CBB) G-250 were from Bio-Rad laboratories (Richmond, CA). Tricine and ε-amino-N-caproic acid were purchased from MP Biochemicals. Bis-Tris was from Calbiochem (La Jolla, CA) and serva Blue G-250 was from Serva (Heidelberg, Germany). Prestained SDS-PAGE markers and native PAGE markers were from Fermentas Life Sciences (Hanover, MD) and Invitrogen (Carlsbad, CA), respectively. PD-10 columns, Q Sepharose Fast Flow, SP Sepharose Fast Flow, ECL Western blotting detection reagents, and Hybond-C nitrocellulose membrane were purchased from GE Healthcare.
The present studies primarily used adult Sprague-Dawley rats from Charles River Laboratories. All animal-related experiments were conducted in adherence with the NIH Guidelines for the Care and Use of Laboratory Animals and were approved by the University of North Texas Health Science Center Animal Care and Use Committee. Where mentioned, adult C57BL/6J mice purchased from the National Institute on Aging were used. For preparation of rat and mouse sera, blood samples were collected from the tail as previously described . For preparation of human serum, blood was drawn from apparent healthy adult volunteers with prior consent. All blood samples were placed at room temperature for 30 min before centrifugation at 3,000 rpm on a benchtop centrifuge. The resulting supernatants containing sera were transferred to clean microtubes, snap-frozen in liquid nitrogen, and stored at −80°C before further analysis. All protein concentrations were determined by the bicinchoninic acid assay  using bovine serum albumin (BSA) as the standard. Rat serum was used throughout the studies unless otherwise specified.
Rat liver or kidney mitochondria were prepared as previously described . Briefly, one gram of liver was homogenized in 10 ml mitochondria isolation buffer containing 70 mM sucrose, 230 mM mannitol, 15 mM MOPS (pH 7.2), and 1 mM EDTA. The homogenate was centrifuged at 700 g for 10 min and the resulting supernatant was collected for further centrifugation at 8,000 g for another 10 min. The resulting pellet containing mitochondria was washed once with the homogenization buffer and centrifuged once again at 8,000 g for 10 min. All the centrifugation steps were performed at 4°C. The isolated mitochondria were either used immediately or stored at −80°C until analysis.
Nongradient blue native polyacrylamide gel electrophoresis (BN-PAGE) was performed as previously described [6, 40]. For in-gel diaphorase activity staining, gel strips were incubated in 50 ml of 50 mM potassium phosphate buffer (pH 7.0) containing 0.2 mg/ml NBT and 0.1 mg/ml NADH . SDS-PAGE was performed according to Laemmli  using a Bio-Rad Mini-PROTEAN III electrophoresis cell. Western blot assay was performed according to Towbin et al.  with slight modifications [48, 49]. All gel images were captured using an EPSON PERFECTION 1670 scanner.
Measurement of DLDH dehydrogenase activity was performed as previously described  with modifications. Typically, the dehydrogenase activity was measured by DLDH-catalyzed oxidation of dihydrolipoamide in the presence of NAD+. The final mixture (1 ml) contained 100 mM potassium phosphate, pH 7.8, 1.0 mM EDTA, 3.0 mM dihydrolipoamide, and 3 mM NAD+. A solution containing all the assay components except dihydrolipoamide was used as the blank. Following 15 min of pre-incubation to eliminate any potential interference effect of serum “nothing dehydrogenase” that is known to reduce NAD+ in the absence of any added substrates [37, 50, 51], the assay was then initiated by the addition of dihydrolipoamide and the increase in absorbance at 340 nm was followed at room temperature for 5 min. An extinction coefficient of 6.22 mM−1cm−1 for NADH was used for the calculation of enzyme activity. DLDH reverse activity, catalyzing the reduction of lipoamide by NADH, was also measured spectrophotometrically as previously described .
Serum diaphorase activity was measured by a method previously described for the measurement of DLDH diaphorase activity . Reduction of 2,6-dichlorophenolindophenol (DCPIP) by NADH was monitored by the decrease in absorbance at 600 nm. The assay (1 ml) contained 50 mM potassium phosphate, pH 7.2, 5 mg serum protein, 1 mM EDTA, 40 μM DCPIP and 0.2 mM NADH. The reaction was initiated by the addition of NADH.
This assay was adapted from a previously published method  that can be used to determine a specific dehydrogenase activity when a corresponding substrate is presented. The method involves electron transfer from NADH, generated by enzyme-dependent reduction of NAD+, to INT via phenazine methosulphate (PMS) as a coupler. In this so-called INT/PMS/NAD method, the final reaction volume was 1 ml in 30 mM Tris-HCl (pH 8.0) containing 0.02% Tween-20, 50 μl serum, 0.6 mg BSA, 20 μM INT, 8 μM PMS, and 4 μM NAD+. The mixture was incubated at room temperature for 10 min followed by addition of appropriate amount of dihydrolipoamide. The reaction mixture was then further incubated at room temperature for another 10 min and the reaction was terminated by addition of 200 μl 0.2 N hydrochloric acid. The absorbance was then measured at 505 nm with blank containing no dihydrolipoamide.
Protein identification was carried out at ProtTech (Norristown, PA) using the NanoLC-MS/MS peptide sequencing technology. Briefly, a given blue native gel band was destained, cleaned, and in-gel digested with sequencing grade trypsin. The resulting peptide mixture was analyzed by an LC-MS/MS system, in which a high pressure liquid chromatography with a reverse phase C18 column (inner diameter: 75 μm) was coupled on-line with an ion trap mass spectrometer. The collected mass spectrometric data were used to search the most recent non-redundant protein database using ProtTech’s proprietary software suite.
Isolation and purification was carried out using conventional procedures, including (NH4)2SO4 fractionation and column chromatography. For partial purification of mitochondrial DLDH, mitochondria were isolated and used for (NH4)2SO4 fractioning. For serum samples, serum was diluted 10 × by 50 mM sodium phosphate (pH 7.4) and the diluted serum sample was used for (NH4)2SO4 fractioning. The procedures for (NH4)2SO4 fractioning of mitochondria and serum were essentially identical and were adapted from previously published DLDH isolation protocols [53–55]. The procedure started with the addition of solid (NH4)2SO4 to achieve 55% saturation. After incubation with gentle stirring at 4°C for 1 h and then centrifugation at 30,000 g for 30 min, the pellet was kept for enzyme analysis while the resulting supernatant was collected and was further brought to 75% saturation by addition of solid (NH4)2SO4. This was followed by incubation and centrifugation under the same conditions to obtain the 55%–75% saturation fraction. For liver tissue, this pellet contained most of mitochondrial DLDH and was then used for further purification by column chromatography as described below.
The protein pellet obtained after 75% (NH4)2SO4 saturation was dissolved in 50 mM HEPES buffer, pH 7.4 and residue (NH4)2SO4 was removed by dialysis against the same HEPES buffer. After concentrating, the sample was applied onto an ion-exchange column (Q Sepharose Fast Flow) that was pre-equilibrated with 100 ml of 50 mM HEPES buffer (pH 7.4). The column was eluted with step-gradient NaCl (50 mM increment/step) in 50 mM HEPES buffer. Fractions containing DLDH were collected and underwent a second cycle of (NH4)2SO4 fractioning. The pellet resulting from 75% saturation was dissolved in 50 mM HEPES buffer (pH 7.4), desalted and concentrated as described above. The concentrated sample was then applied onto a cation exchange column (SP Sepharose Fast Flow) that was pre-equilibrated with 100 ml of 50 mM HEPES buffer (pH 7.4). This was followed by elution of the column with step-gradient NaCl (20 mM increment/step) in 50 mM HEPES buffer. Fractions containing DLDH were collected and underwent a third cycle of (NH4)2SO4 fractioning. The final pellet obtained after 75% saturation was dissolved in 20 mM potassium phosphate buffer (pH 7.0), desalted and concentrated. The sample was then applied onto a hydroxyapatite column pre-equilibrated with potassium phosphate buffer (pH 7.0). The column was eluted with increasing concentration of potassium phosphate buffer (pH 7.0, 40 mM per increment). Fractions containing DLDH were collected and concentrated for further analysis.
We previously noted briefly the identification of DLDH in rat serum in an unrelated study . Herein we present the detailed results of this identification. In proteomic studies of rat serum proteins analyzed by BN-PAGE and mass spectrometry peptide sequencing, we found that one band contained DLDH . Fig. 1 shows a mass spectrum demonstrating the identification of a serum DLDH peptide, whereby a typical blue native gel image indicating the localization of DLDH is also shown (band 5, the inset). A total of six tryptic peptides that matched to rat mitochondrial DLDH were identified (Table 1). These results provide proteomic evidence that DLDH is present in rat serum.
Interestingly, when we analyzed serum DLDH using Western blot assay, serum DLDH immunostaining was not detected (Fig. 2), though mitochondrial DLDH could be well-localized on the same blot (Fig. 2). The reason that the antibodies recognizing mitochondrial DLDH failed to detect serum DLDH remains unknown. When we measured serum DLDH dehydrogenase activity by spectrophotometric assay, we found that the activity could be measured under normal physiological conditions in all the three mammalian species including rat, human, and mouse (Fig. 3A), and the use of 5 mg serum protein gave a satisfactory result. Moreover, serum DLDH activity, as assayed by the INT/PMS/NAD method , was dependent on both substrate concentration (Fig. 3B) and serum volume (Fig. 3C). It should be noted that the dehydrogenase activity in serum was very low when compared with that in mitochondria. For example, under our experimental conditions, DLDH dehydrogenase activity in isolated mitochondria was 217 mUnit/mg mitochondrial protein (n=6), while this value in serum was 0.024 mUnit/mg serum protein (n=5). Such comparison suggests that DLDH is present in a very low abundance in serum. Nevertheless, these measurements are in agreement with previous reports that DLDH activity could be detected in human serum and the enzyme assay was generally protein concentration- and substrate concentration dependent [37, 39]. Additionally, the pronounced fall-off of the absorbance curves in Fig. 3A was likely due to product inhibition by NADH, as has been established for mitochondrial DLDH [56–59].
We next investigated whether serum DLDH diaphorase activity, if any, could be measured by an in-gel activity staining method that we previously described for the measurement of mitochondrial DLDH diaphorase . As shown in Fig. 4A, no serum DLDH diaphorase activity could be detected while mitochondrial DLDH showed an intensive activity staining (the left lane). On the other hand, DLDH-catalyzed reverse reaction, in which lipoamide is reduced at the expense of NADH, was clearly detectable (Fig. 4B). Interestingly, there was a diaphorase activity in serum that could be detected spectrophotometrically by DCPIP in the presence of NADH (Fig. 4B). However, given the undetectable diaphorase activity in Fig. 4A, this diaphorase activity was likely contributed by other NADH-dependent enzymes in the serum [60, 61]. These results are in agreement with previous studies that serum DLDH lacks diaphorase activity [37, 39].
When we attempted to purify serum DLDH by following its diaphorase activity determined by BN-PAGE, we found that no DLDH diaphorase activities could be detected in any of the (NH4)2SO4 fractions (Fig. 5A). This was very different from that of mitochondria (NH4)2SO4 fractionation whereby DLDH diaphorase activity could be clearly detected and majority of the activity was in the 55–75% saturation fraction (Fig. 5B). Therefore, even for concentrated and fractionated serum samples, no DLDH diaphorase activity was detectable. Moreover, no serum DLDH dehydrogenase activity could be detected spectrophotometrically in the (NH4)2SO4 fractions, indicating that serum DLDH activity was lost after (NH4)2SO4 fractioning. Likewise, no enzyme activity could be detected after serum samples underwent gel filtration on PD-10 columns (Fig. 5C). In contrast, there was no loss in mitochondrial DLDH activity after PD-10 gel filtration (Fig. 5D). To further confirm that there was indeed a loss in serum dehydrogenase activity after gel filtration, we also measured DLDH dehydrogenase activity in the gel-filtered samples by the INT/PMS/NAD method  in a separate experiment. Fig. 5E shows that there was more than 50% loss in enzyme activity after one-step gel filtration of serum samples, demonstrating that serum DLDH is indeed vulnerable to procedures of further isolation and purification, regardless of the methods used for measurement of enzyme activities. It should be noted that under our experimental conditions, the INT/PMS/NAD method appears to be more sensitive than the assay relying on direct measurement of NADH produced by dihydrolipoamide reduction of NAD+.
As a further comparison of the enzyme stability between serum and mitochondrial DLDH, the enzyme partially purified from rat liver mitochondria after many steps of (NH4)2SO4 fractioning and column chromatography (Fig. 6A) still remained active (Fig. 6B, control), and the activity could only be intentionally and significantly attenuated by treatment with oxidants such as peroxynitrite (Fig. 6B), a chemical that is known to inhibit enzyme activity due to its ability to induce protein carbonylation and S-nitrosylation [62, 63]. While DLDH can be inhibited by a variety of chemicals such as thiol alkylating reagents , heavy metals , valproic acid metabolites , diphenyleneiodonium , and 5-methoxyindole-2-carboxylic acid (MICA) [68–70], we chose peroxynitrite in this study because our long-term research interest is to understand the roles of DLDH oxidative modifications in disease and health [71–73]. Fig. 6B also shows that peroxynitrite might react with DLDH’s substrate dihydrolipoamide or the product NADH in the assay solution as the loss of enzyme activity in the presence of peroxynitrite alone was apparently over estimated when compared with that in the presence of GSH, a well-known peroxynitrite scavenger . Nevertheless, loss of DLDH activity in the presence of GSH was still significant when compared with that of control, demonstrating an authentic action of peroxynitrite on DLDH.
The loss of DLDH enzyme activity after gel filtration or (NH4)2SO4 precipitation is intriguing. Given the fact that xanthine dehydrogenase is very sensitive to oxygen attack and can be converted to xanthine oxidase after exposure to atmospheric oxygen during isolation and purification [75, 76], we reasoned that the loss of DLDH activity after (NH4)2SO4 precipitation and gel filtration might also be caused by atmospheric oxygen exposure. To test this possibility, we attempted to prevent oxygen exposure by supplementing DTT (final concentration: 10 mM) in both the serum and the gel filtration buffer (50 mM Tris-HCl, pH 7.4) that was used for column equilibration and elution. Based on previous findings that EDTA protects hydrogenase against air-inactivation via iron chelation  and that fluorocitrate, an aconitase inhibitor, protects aconitase against air-inactivation  via physical binding during isolation of each respective enzymes, we also tested the effects of EDTA (5 mM) and DLDH inhibitor MICA (0.5 mM) [68–70] on DLDH activity after gel filtration. Results in Fig. 7 show that while the presence of either EDTA or MICA in the equilibration and elution buffer did not prevent loss of DLDH activity after gel filtration, the presence of DTT in the same buffer largely preserved DLDH activity that, otherwise, would be lost after gel filtration, demonstrating that serum DLDH is sensitive to atmospheric oxygen inactivation. These results also indicate that, during gel filtration, binding of MICA to DLDH has no protective effect on air-inactivation of the enzyme, and that DLDH inactivation is not due to any presence of iron that might be potentially released from blood during preparation of serum samples. It should be noted that the protective effect of DTT could not last for more than 60 min after gel filtration, probably because DTT also underwent auto-oxidation by ambient oxygen (data not shown).
The major findings of the present study are that both the forward and the reverse activities of DLDH can be readily lost after (NH4)2SO4 fractioning or gel filtration of serum samples and such loss of activity is likely caused by exposure to atmospheric oxygen during isolation. Results of the present study demonstrate that serum DLDH is a very labile enzyme.
DLDH has previously been considered as a serological diagnostic in metabolic disease , although attempts to use this serum protein as a biomarker for Fredreich’s ataxia [38, 79, 80] proved to be controversial , perhaps because the serum DLDH protein was not clearly identified or well characterized. The present study provides the first peptide sequencing evidence that DLDH exists in rat serum (Fig. 1 and Table 1), and spectrophotometrically confirms previous reports that human serum contains DLDH (Fig. 3). Measurement of enzyme activity by spectrophotometric assay also indicates the existence of DLDH in mouse serum. Interestingly, our results indicate that serum DLDH is a very labile enzyme. This is in contrary to mitochondrial DLDH that is highly stable and makes it impossible to follow the enzyme’s activity during isolation and purification. Hence our attempt to purify enough of this serum enzyme for further biochemical characterization failed.
It might be argued that the reason that serum DLDH activity is undetectable after (NH4)2SO4 precipitation or native gel electrophoresis is because this enzyme has an extremely low content in the serum. However, the enzyme activity was certainly detectable in the original serum, whereby the volume of which was normalized to that after PD-10 gel filtration so that the enzyme activity could be compared on a same volume basis before and after PD-10 columns. Despite this normalization, there was a dramatic loss of activity after PD-10 gel filtration (Fig. 5, C and E) while mitochondrial DLDH treated similarly fully retained its activity (Fig. 5D). These lines of evidence led us to conclude that serum DLDH is a labile enzyme. The possibility for loss of DLDH activity could be due to the fact that serum has a reducing environment because of the existence of albumin and glutathione  and this reducing environment is perturbed during gel filtration, which makes DLDH vulnerable to oxygen exposure. This reasoning would be in agreement with our findings that DTT protected DLDH against air-inactivation when supplemented in serum and in the gel filtration buffer (Fig. 7), although the mechanisms underlying DLDH’s vulnerability to air-inactivation remains unknown at this point. Interestingly, in contrast to that of DTT, we did not observe any protection from EDTA supplemented in both the gel-filtration buffer and the serum, suggesting that EDTA-chelatable metals such as iron or zinc are not involved in DLDH inactivation during the gel filtration process. Nonetheless, our results do not exclude the possibility that non-EDAT chelatable metals are involved in DLDH inactivation during isolation and purification under our experimental conditions.
Another possibility for loss of DLDH activity during isolation and purification could be due to H2O2 generated by DLDH itself. This is possible because DLDH is known to be capable of producing H2O2 under appropriate conditions [15, 82–85]. Additionally, loss of DLDH activity could also be caused by conditions or disruptions favoring the formation of DLDH monomeric state  or 4-electron-reduced state  that exhibit a higher or only diaphorase activity but a lower or none dehydrogenase activity. Further, it is also known that DLDH in diluted solution is not as stable as that in mitochondria  and DLDH monomer actually exhibits protease properties . These findings may render DLDH behavior in serum less predictable. In any case, the exact mechanisms by which DLDH loses its activity during isolation and purification needs further investigations. Nonetheless, we speculate that cysteine oxidation on DLDH could be a reason for the loss of DLDH activity as cysteine residues are redox sensitive  and DLDH cysteines are known to be susceptible to oxidative modifications [45, 71–73].
The origin of serum DLDH remains unknown. It has been suggested that liver could be the source of serum DLDH . However, there have been no reports that DLDH isoforms exist in liver. If serum DLDH indeed originates from liver mitochondria, then it would be very difficult to explain the loss of serum DLDH activity following isolation or purification procedures. This is because mitochondrial DLDH is extremely stable, as shown in this and previous studies . On the other hand, if serum DLDH results from cell destruction in tissues of origin, it would also be difficult to explain why only DLDH, other than other mitochondrial proteins, is detectable when all the visible BN-PAGE bands were sequenced . All these results indicate that it is unlikely that serum samples used in our studies were contaminated by mitochondria. Additionally, mitochondrial DLDH could still remain active after heating at 75°C for 5 min , a property that has been repeatedly used as a key step in isolation and purification of mitochondrial DLDH . In contrast, as reported in this study, serum DLDH is very labile and any further manipulation procedures would lead to severe loss of enzyme activity. Given the establishment that many mitochondrial proteins, including superoxide dismutase , fumerase , glutathione S-transferase , aconitase [94, 95] and plant glutathione reductase , have been found to also localize outside mitochondria, a phenomenon termed as dual localization of echoforms of mitochondrial proteins [92, 97–99], we speculate that serum DLDH is secreted into the circulation system and could be another mitochondrial protein that is dual-localized. Interestingly, it has been reported that mitochondrial DLDH amino acid composition possesses dual localization properties  and DLDH can exist extra-mitochondrially in mammalian spermatozoa . Regardless, whether or not DLDH is a dual localized protein also awaits further studies.
Finally, the biological function of serum DLDH remains obscure at this time. However, we speculate that this serum protein could be involved in maintaining a proper redox balance between lipoamide and dihydrolipoamide, or between lipoic acid and dihydrolipoic acid. Both pairs of these small molecules are known to exist in the blood [102–104]. In this sense, serum DLDH is distinct from its classical role in the 2-oxo acid dehydrogenase complexes. In fact, DLDH is known to be involved in antioxidant defense systems [12, 85, 105], and can exist as a non-complexed form in mammalian tissues , and has also been found to be expressed in organisms that do not have 2-oxo-acid dehydrogenase complexes [107–110]. All these studies further indicate that DLDH has other biological functions.
We provided proteomic evidence that DLDH exists in serum and found that while serum DLDH also catalyzes the physiological reaction of dihydrolipoamide reoxidation using NAD+ as the electron acceptor; it differs from mitochondrial DLDH in several aspects. These include loss of activity after further procedures of isolation or purification due to its susceptibility to atmospheric oxygen inactivation, lack of diaphorase activity, and failure to be recognized by antibodies that recognize mitochondrial DLDH. These distinct properties of serum DLDH raise the question of whether this serum protein could be a form that is different from mitochondrial DLDH. Future studies will be needed to determine the biological function of this serum protein and the mechanisms underlying its susceptibility to air-implicated inactivation. Additionally, whether or not this serum enzyme could be an isoform or an echoform [92, 97, 98] of mitochondrial DLDH will also need to be investigated.
This work was supported in part by a UNTHSC-UAEM research seed grant (RI6044) and a National Institute on Aging grant (AG022550). The authors thank Dr. Drake Zhang and Ms. Kerri Jin at ProtTech for their assistance in mass spectrometry peptide sequencing.
Conflict of interest: None declared.